Buy rating on Emami; Handsome gains: Nomura Emami Handsome rating: Results were above our estimates. Sales were 3.5% above our estimates. Profit after tax was 13% above… By NomuraUpdated: May 25, 2015 10:00 IST
Buy UltraTech Cement, target Rs 3,290: Nomura Maintain ‘buy’ on UltraTech Cement with a price target of R3,290 a share. We value the company at 12.5x EV/Ebitda,… By NomuraMay 22, 2015 00:13 IST
Cadila beats estimates, US market the key: Nomura Cadila Healthcare’s (CDH) Q4 results were above our expectations. Revenue recorded a 16% growth… By NomuraMay 21, 2015 00:15 IST
Retain buy on Torrent Pharma: Nomura Maintain ‘buy’ on Torrent Pharma with an increased target price of R1,373 (earlier Rs 1,278). By NomuraMay 20, 2015 00:14 IST
Buy Jubilant Life on possibility of biz revival in Q4: Nomura Jubilant Lifescience’s (JOL) sales/Ebitda in Q4 were 4%/24% ahead of consensus expectations… By NomuraMay 15, 2015 00:14 IST
Havells stock prices in weak Q4 earnings: Nomura Havell’s standalone Q4FY15 earnings missed our as well as the Street’s expectations by 5%/3%, as sales declined… By NomuraMay 13, 2015 00:11 IST
‘Neutral’ rating on Kotak Mahindra Bank: Street beater Risks from ING Vysya consolidation fairly low now. By NomuraMay 11, 2015 00:05 IST
Captive coal availability key trigger for NTPC; maintain buy: Nomura Based on our recent meetings with NTPC’s management, while there is no new path-breaking catalyst… By NomuraMay 9, 2015 00:15 IST
Petronet LNG a compelling growth story despite near term concerns: Nomura While the market is concerned over the poor demand for the highly-priced RasGas long-term LNG… By NomuraMay 8, 2015 00:18 IST
Reliance Power’s exit of Tilaiya UMPP calculated move: Nomura Reliance Power was awarded the Tilaiya UMPP in February 2009 via tariff-based biddin. By NomuraApril 30, 2015 01:33 IST
Maintain reduce on JSW Energy as stock tad overvalued: Nomura JSW has declared a dividend of R2 per share (same level as in FY14), implying a payout of 30%. By NomuraApril 29, 2015 01:15 IST
Robust fee and loan growth: Buy rating for IndusInd Bank Valuations could remain high on potential profitability surprises By NomuraUpdated: April 27, 2015 04:59 IST
Neutral on Cairn India, near-term outlook weaker Retain ‘neutral’ rating on Cairn India with a target price of Rs 235 per share. By NomuraApril 25, 2015 00:09 IST
Buy SHTF as risk, reward favourable: Nomura Retain ‘buy’ on Shriram Transport Finance (SHTF). We view the recent price correction as a good opportunity to accumulate the… By NomuraApril 22, 2015 00:12 IST
Neutral on ACC due to mixed results in Q1 Remain ‘neutral’ on ACC and roll-forward our target by three months to a one-year forward price of Rs 1,528 per… By NomuraApril 16, 2015 00:17 IST
DRL discloses robust product pipeline: Nomura Dr Reddy’s Laboratories (DRL) has disclosed that it has made three NDA filings with the US FDA, more than its… By NomuraApril 11, 2015 00:07 IST
Buy DRL as UCB buy incrementally positive Reiterate ‘buy’ on Dr Reddy’s Laboratories and value the stock at 20x FY17 EPS forecast of Rs 177.5, which derives… By NomuraApril 9, 2015 02:49 IST
MMFS lacks case for robust growth in long term: Nomura Remain ‘neutral’ on M&M Financial Services (MMFS) with target price of R290 per share, implying implies 2x Mar-17 book… By NomuraApril 1, 2015 00:17 IST
Perfect Schengen visa application rejected, messy applicant awarded one year visa- Reddit user reveals why
